Micromet Inc (MITI)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

2110 RUTHERFORD CARLSBAD, CA 92008

Micromet, Inc., a biopharmaceutical company, develops antibody-based products for cancer, inflammatory, and autoimmune diseases. Its products under clinical trials include MT103, a Phase I clinical trial product candidate for the treatment of patients with non-Hodgkins lymphoma; and Adecatumumab, a recombinant human monoclonal antibody that is under clinical Phase IIa status for metastatic breast cancer and other adenocarcinoma indications, and is being evaluated in clinical Phase Ib trials for treatment of metastatic breast cancer in combination with docetaxel. The company's preclinical development products include MT203 and MT204 human antibodies to treat various acute and chronic inflammatory diseases, including rheumatoid arthritis, asthma, psoriasis, and multiple sclerosis; EphA2, a cell surface membrane-associated receptor tyrosine kinase for the treatment of cancer; CEA, which is indicated for the treatment of tumors of epithelial origin, such as colorectal carcinoma, lung adenocarcinoma, mucinous ovarian carcinoma, and endometrial adenocarcinoma; MORAb28, a human IgM monoclonal antibody binding to an antigen that is identified as a cell-surface antigen present on human melanomas and tumors of neuroectodermal origin; and MT110, a molecule that combines binding specificities for EpCAM and for CD3 on T cells. Micromet's product pipeline also consists of D93, a humanized, anti-metastatic, and anti-angiogenic monoclonal antibody for treatment of patients with solid tumors. It has strategic collaborations with MedImmune, Inc. for MT103; Nycomed for development of anti-GM-CSF antibodies; and Merck Serono Biopharmaceuticals S.A. for adecatumumab.

View SEC Filings from MITI instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding MITI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MITI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GRAU ULRICH M EVP AND COO

  • Officer
No longer subject to file 2012-03-07 0

LOBACKI JOSEPH M SVP & CHIEF COMMERCIAL OFFICER

  • Officer
No longer subject to file 2012-03-07 0

JOHANN PETER

  • Director
No longer subject to file 2012-03-07 0

BAEUERLE PATRICK SVP, CSO

  • Officer
No longer subject to file 2012-03-07 0

BERRIMAN JOHN E

  • Director
No longer subject to file 2012-03-07 0

HALE DAVID F

  • Director
No longer subject to file 2012-03-07 0

CARTER MICHAEL G

  • Director
No longer subject to file 2012-03-07 0

ITIN CHRISTIAN PRESIDENT AND CEO

  • Officer
No longer subject to file 2012-03-07 0

PHILLIPS BARCLAY A SVP, CFO

  • Officer
No longer subject to file 2012-03-07 0

SLATTERY JOSEPH P

  • Director
No longer subject to file 2012-03-07 0

FAGERBERG JAN SVP, CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2012-03-07 0

ALDER MATTHIAS SVP, GC AND SECRETARY

  • Officer
No longer subject to file 2012-03-07 0

HENNECKE JENS SVP, BUSINESS DEVELOPMENT

  • Officer
No longer subject to file 2012-03-07 0

AMGEN INC

ARMSTRONG ACQUISITION CORP.

  • 10% Owner
No longer subject to file 2012-03-06 0

BRADWAY ROBERT A

  • Director
0 2012-03-02 0

HARPER SEAN E

  • Director
0 2012-03-02 0

MCNAMEE BRIAN M

  • Director
0 2012-03-02 0

SHARER KEVIN W

  • Director
0 2012-03-02 0

SCOTT DAVID J

  • Director
0 2012-03-02 0

PEACOCK JONATHAN M

  • Director
0 2012-03-02 0

DHINGRA KAPIL

  • Director
0 2011-06-23 0

REISENAUER MARK L SVP, CHIEF COMMERCIAL OFFICER

  • Officer
0 2011-03-16 0

BENJAMIN JERRY

  • Director
0 2010-06-22 0

STAMPACCHIA OTELLO

  • Director
2,197,413 2010-03-02 0

OMEGA FUND MANAGEMENT LTD

SIGMA HOLDING LTD

HELYAR CONNIE

ALVAREZ-MASTERTON SHARON ROSE

  • 10% Owner
No longer subject to file 2009-08-04 0

OMEGA FUND MANAGEMENT LTD

SIGMA HOLDING LTD

STAMPACCHIA OTELLO

HELYAR CONNIE

ALVAREZ-MASTERTON SHARON ROSE

  • Director
  • 10% Owner
4,454,313 2009-07-31 0

REINHARDT CARSTEN SVP & CMO

  • Officer
0 2009-04-01 0

ZELM DONALD A CHIEF FINANCIAL OFFICER

  • Officer
0 2008-05-01 0

ALVAREZ-MASTERTON SHARON ROSE

  • 10% Owner
4,892,813 2008-01-14 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments